VRDN News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VR

Mkt Cap

$2.22B

Volume

1.98M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionHighVista Strategies sold 238,243 shares of Viridian Therapeutics (worth ~$7.08 million) in Q1 2026, reducing its position by $8.97 million when accounting for stock price movements. The sale may reflect profit-taking ahead of the company's June 30 FDA decision on its lead therapy veligrotug. Despite recent stock volatility following Phase 3 data that beat expectations, Viridian remains positioned as a potential commercial player in the thyroid eye disease market with its subcutaneous candidate elegrobart.The Motley Fool · May 17, 2026

Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should KnowKopp Family Office reduced its Viridian Therapeutics stake by 117,878 shares ($3.5M) in Q1 2026, cutting the position from 3.4% to 0.7% of AUM. The move appears prescient as Viridian shares have fallen 50% since mid-March following disappointing Phase 3 data for elegrobart and stronger competing results from Amgen's Tepezza variant, raising questions about market differentiation for the clinical-stage biotech.The Motley Fool · Apr 21, 2026

J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesJohnson Fistel, PLLC is investigating potential securities fraud claims on behalf of investors in J.Jill, RH, and Viridian Therapeutics. The J.Jill investigation was prompted by the company's March 31, 2026 earnings disclosure revealing poor holiday assortment performance, increased competitive promotions, and customer migration toward discounted pricing, raising questions about compliance with federal securities laws.GlobeNewswire Inc. · Apr 1, 2026

Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesJohnson Fistel, PLLP announced investigations into potential securities law violations by Viridian Therapeutics, Braskem S.A., and TAT Technologies Ltd. on behalf of investors who suffered losses. The investigation into Viridian focuses on whether the company complied with federal securities laws following its announcement of Phase 3 clinical trial results for its REVEAL-1 trial.GlobeNewswire Inc. · Mar 31, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million StakeCommodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.The Motley Fool · Feb 23, 2026

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.Benzinga · Dec 31, 2025

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To BenefitArgenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.Benzinga · Dec 15, 2025

4DMT Appoints Kristian Humer as Chief Financial Officer4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.GlobeNewswire Inc. · Nov 17, 2025

Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.GlobeNewswire Inc. · Oct 16, 2025

10 Health Care Stocks With Whale Alerts In Today's SessionMultiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.Benzinga · Sep 29, 2025

VR

VRDNViridian Therapeutics, Inc. Common Stock

VRDN

Pay with—

Available Balance0.00

Your PositionYou don't own any VRDN yet.

Related Tickers

Earnings